تونس -
العربية -
Ministère de la Santé, Direction de l'inspection Pharmaceutique
glucose 10% infomed solution injectable pour perfusion
إسرائيل -
العربية -
Ministry of Health
مونتيلوكاست تيڤع ۱٠ ملغ
teva pharmaceutical indust.ltd - montelukast as sodium 10 mg - tablets - montelukast - montelukast teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.
إسرائيل -
العربية -
Ministry of Health
تريتايس ٢٫٥ ملغ
sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
